Description
Pasireotide Ditrifluoroacetate, also known as SOM230 TFA salt, is a long-acting cyclohexapeptide analog of somatostatin designed to target multiple somatostatin receptor subtypes. Research indicates it improves agonist activity compared to earlier analogs. The product is manufactured to GMP standards and tested to have a purity of 99.56%, making it ideal for research in endocrinology, neuropharmacology, and oncology models.
Product Specifications
| Parameter | Details |
|---|---|
| Product Name | Pasireotide Ditrifluoroacetate |
| Purity | 99.56% (HPLC) |
| Salt Form | TFA (trifluoroacetate) salt |
| Appearance | White to off-white solid |
| Applications | Somatostatin receptor research, multi-receptor pharmacology |
| Manufacturing Standard | GMP-compliant |
| Regulatory Status | For laboratory research use only |
Mechanism of Action & Research Applications
Pasireotide is a synthetic somatostatin analog with high affinity for multiple somatostatin receptors (especially SSTR5). It exerts antisecretory, antiproliferative, and proapoptotic effects, making it a valuable research tool in studying hormone secretion, tumor growth, and receptor pharmacology.
Disclaimer
This product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Please handle according to institutional safety protocols.


Reviews
There are no reviews yet.